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Aims To examine pericoronary adipose tissue (PCAT) and periaortic adipose tissue (PAAT) density on coronary com-




PCAT and PAAT density was measured in coronary (n = 1016) and aortic (n = 108) segments from 108 subjects
[TAK þ coronary artery disease (CAD), n = 36; TAK, n = 18; atherosclerotic CAD, n = 32; matched controls,
n = 22]. Median PCAT and PAAT densities varied between groups (mPCAT: P < 0.0001; PAAT: P = 0.0002). PCAT
density was 7.01 ± standard error of the mean (SEM) 1.78 Hounsfield Unit (HU) higher in coronary segments from
TAK þ CAD patients than stable CAD patients (P = 0.0002), and 8.20 ± SEM 2.04 HU higher in TAK patients with-
out CAD than controls (P = 0.0001). mPCAT density was correlated with Indian Takayasu Clinical Activity Score
(r = 0.43, P = 0.001) and C-reactive protein (r = 0.41, P < 0.0001) and was higher in active vs. inactive TAK
(P = 0.002). mPCAT density above -74 HU had 100% sensitivity and 95% specificity for differentiating active TAK
from controls [area under the curve = 0.99 (95% confidence interval 0.97–1)]. The association of PCAT density
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and coronary arterial inflammation measured by 68Ga-DOTATATE positron emission tomography (PET) equated
to an increase of 2.44 ± SEM 0.77 HU in PCAT density for each unit increase in 68Ga-DOTATATE maximum
tissue-to-blood ratio (P = 0.002). These findings remained in multivariable sensitivity analyses adjusted for potential
confounders.
...................................................................................................................................................................................................
Conclusions PCAT and PAAT density are higher in TAK than atherosclerotic CAD or controls and are associated with clinical,
biochemical, and PET markers of inflammation. Owing to excellent diagnostic accuracy, PCAT density could be
useful as a clinical adjunct for assessing disease activity in TAK.
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Introduction
Takayasu arteritis (TAK) is a rare large-vessel vasculitis characterized
by pan-arterial granulomatous inflammation that typically affects
young women, leading to progressive injury of the aorta and its major
branches.1 Coronary artery involvement in TAK is well-described,
but clinically under-recognized. Ostial lesions, aneurysms, and fibrotic
stenoses often go undetected until a late, burnt-out stage in the dis-
ease when therapies are less effective. Accelerated atherosclerosis is
another common feature in TAK, related to chronic inflammation.
Although treatment of coronary arteritis differs from atherosclerosis,
conventional imaging modalities are unable to accurately distinguish
vasculitic from atherosclerotic processes or quantify disease activity.
Pericoronary adipose tissue (PCAT) density on coronary computed
tomography angiography (CCTA) is a promising imaging biomarker
for assessing coronary arterial inflammation. Experimental data indi-
cate that inflammation related to arterial injury manifests phenotypic
changes in perivascular adipose tissue due to pro-inflammatory cyto-
kine paracrine signalling and its effects on lipolysis and adipogenesis
leading to altered adipocyte size and volume.2 These changes in adipo-
cyte size and lipid/water content can be detected in the tissue sur-
rounding the coronary vasculature by CCTA, using fat attenuation
index (FAI),3 or another highly reproducible method for quantifying
PCAT density derived from semi-automated plaque analysis software.4
In this study, PCAT and periaortic adipose tissue (PAAT) density
were compared in patients with TAK ± coronary artery disease
Graphical Abstract
In this observational study, pericoronary adipose tissue (PCAT) density demonstrated good diagnostic accuracy for Takayasu arteritis ± coronary artery
disease (CAD) and was associated with clinical markers of inflammation and disease activity. Median PCAT density values for all major epicardial coronary
artery segments displayed.
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(CAD) to patients with atherosclerotic CAD, and matched control
subjects. PCAT and PAAT density were also compared with clinical
markers of disease activity, and, in a nested sub-analysis, with coron-
ary artery inflammation measured by 68Ga-DOTA-(Tyr3)-octreotate
(DOTATATE) positron emission tomography (PET) imaging. 68Ga-
DOTATATE is a clinical PET tracer used in oncology imaging, which
binds somatostatin receptors. As somatostatin receptor-2 is expressed
by activated macrophages, 68Ga-DOTATATE PET has been re-
purposed as marker of vascular inflammation in the context of re-
search. Unlike 18F-fluorodeoxyglucose (FDG), 68Ga-DOTATATE
exhibits low background myocardial activity allowing clear coronary
signal interpretation.5 Ultimately, as periarterial adipose tissue density
is associated with inflammation in atherosclerosis, we sought to deter-
mine whether PCAT or PAAT density could also be a useful marker of
inflammatory disease activity in TAK.
Methods
Study design and participants
In this observational study, CCTAs were identified from consenting partici-
pants who underwent imaging as part of prospective research studies
[PITA (PET Imaging of giant-cell and Takayasu Arteritis), NCT04071691;
RIPPLE (Residual Inflammation and Plaque Progression Long-term
Evaluation), NCT04073810; VISION (Vascular Inflammation imaging using
Somatostatin receptor positron emissION tomography), NCT02021188]
or clinical care at Addenbrooke’s Hospital, Cambridge, UK and
Hammersmith Hospital, London, UK from 2014 to 2020. Data from all par-
ticipants in these multi-modality imaging studies who had contemporaneous
high-quality CCTAs performed on a dedicated computed tomography
(CT) scanner were included in the present analysis. Participants were
included with, (i) TAK and CAD; (ii) TAK and no CAD; (iii) atherosclerotic
CAD; and (iv) no TAK or CAD. CAD status was defined by CCTA.
Consecutive control subjects were age-matched with the TAK
patients, and also matched for body-mass index and CT tube voltage (kV)
with all groups. Similar numbers of male and female control subjects
were selected. Due to inherent differences in demographic trends be-
tween TAK and atherosclerotic CAD, these groups were not matched
using propensity scoring or another method as this would compromise
the generalizability of the findings by creating samples no longer represen-
tative of the true populations. Participants with chronic renal failure or
other contra-indications to CCTA were excluded. Full inclusion and ex-
clusion criteria of the original clinical studies are in the Supplementary
material online. Research was conducted with the approval of the local
research ethics committee (REC 19/EE/0043; 14/EE/0019), in accordance
with the Declaration of Helsinki.
Clinical data
Baseline clinical data were recorded. Independent of this study, TAK
patients were graded by an experienced vascular rheumatologist accord-
ing to the Indian Takayasu Clinical Activity Score (ITAS-CRP).
Cardiovascular risk was scored using the U-prevent algorithm (https://u-
prevent.com/calculators).
Image acquisition and reconstruction
CCTA imaging
CCTA was performed using a dedicated 64-slice (SOMATOM
Definition, Siemens Healthcare) or 2  64-slice (Definition Flash,
Siemens Healthcare) cardiac scanner from the same vendor, following a
standard clinical protocol consistent across both hospitals. Sublingual
glyceryl trinitrate (400mg) ±intravenous metoprolol (5–20 mg) was given
provided there was no contraindication. Intravenous contrast (NIOPAM
350, Bracco) was administered with a 0.9% saline flush. Prospective or
retrospective CCTA images were acquired during end-inspiration with
the patients’ arms raised, tube current (smart mA) and voltage (80–
140 kV) adjusted for body size and reconstructed at 0.75-mm slice thick-
ness (kernel B26f).
PET imaging
68Ga-DOTATATE imaging was performed in patients with TAK and
patients with recent myocardial infarction (MI) using a PET/magnetic res-
onance scanner (SIGNA, GE Healthcare), with a target injected tracer ac-
tivity of 250 MBq and 30-min cardiac image acquisition after a 50-min
uptake period. Images were reconstructed from list mode data in eight
cardiac bins with time-of-flight iterative reconstruction that included
point-spread function modelling, using a two-point DIXON magnetic res-
onance sequence for attenuation correction.
Patients with atherosclerotic CAD underwent 68Ga-DOTATATE
imaging on a PET/CT scanner (Discovery 690, GE Healthcare, USA) as
previously described.5 PET/CT images were reconstructed from list
mode data in four cardiac bins, using time-of-flight ordered-subset ex-
pectation maximization (256  256 matrix, 3 iterations, 24 subsets, 2.0-




Semi-automated vessel segmentation, quantitative plaque analysis, and
measurement of PCAT density were performed around epicardial coron-
ary artery segments with diameter >_2 mm using a validated and reprodu-
cible method (Autoplaque version 2.5, Cedars Sinai Medical Centre).4
Poor-quality CCTAs and segments with stent-related artefacts were
excluded. PCAT density was determined automatically as the mean at-
tenuation in Hounsfield Unit (HU) of voxels with tissue ranging from
-190 up to -30 HU within a predefined volume of interest located in a 3-
mm radius of the outer coronary wall. Median PCAT density in each pa-
tient was calculated for all coronary segments (mPCATtotal), in proximal
segments (mPCATprox), and in proximal right coronary artery segments
(mPCATpRCA). PAAT density was measured in a 3 cm segment of the
proximal ascending aorta contiguous with the sinotubular junction.
PETanalysis
Coronary 68Ga-DOTATATE PET was analysed using cardiac motion-
corrected and co-registered PET and CCTA datasets following an estab-
lished technique (FusionQuant version 1.19.4.4, Cedars Sinai Medical
Centre),6 to derive maximum tissue-to-blood ratio (TBRmax) corrected
for average blood pool activity in the superior vena cava. Distal right cor-
onary artery segments with nearby high liver uptake were excluded from
the analysis.
Statistical analysis
PCAT and PAAT density expressed as median [interquartile range (IQR)]
were compared by group using the Kruskal–Wallis test, and with clinical
data using Spearman’s rank correlation. Receiver operating characteristic
(ROC) analyses were constructed to assess the diagnostic accuracy of
PCAT and PAAT density for disease groups and disease activity status.
Univariable linear mixed-effects models were employed to account for a
hierarchical data structure when comparing observations from multiple
coronary segments from the same patient. Patient effects were incorpo-
rated as random intercepts in the models. The fixed effects were reported
as effect size (also known as slope estimate) ± standard error of the mean





















..(SEM). Potential confounding factors associated with PCAT density
(P < 0.1) in univariable linear mixed-effects models were included in multi-
variable sensitivity analyses to assess the robustness of the main study find-
ings. Normality of the residuals after regression was assessed using the
quantile-quantile plot. A two-sided P-value of <0.05 was considered signifi-
cant. Statistical analyses were performed using R statistical analysis program
(Version 4.0.2) and Prism (Version 9.0.2, GraphPad).
Results
Patients
One hundred and eight subjects (54 TAK and 54 non-TAK) were
included (TAK þ CAD, n = 36; TAK, n = 18; atherosclerotic CAD,
n = 32; controls, n = 22; Graphical abstract; Supplementary material on-
line, Figure S1). TAK and control groups were well-matched for age
(median 51 vs. 52 years), body mass index (median 27 vs. 27 kg/m2),
and kV (median 120 vs. 120; Table 1). TAK patients were predomin-
antly female and younger than atherosclerotic CAD patients, with
greater high-sensitivity C-reactive protein concentrations and lower
10-year %cardiovascular risk. In the TAK groups, 28% (15/54) had
clinically active disease (ITAS-CRP score >_ 2), 63% (34/54) had aortic
thickening, 39% (21/54) had ostial coronary lesions and one patient
had coronary aneurysms (Figure 1). Mean ITAS-CRP score was
1 ± SD 2 in TAK patients, with no difference between TAK groups.
There was a median 37 (IQR 20–120) days between blood tests and
CCTA. One TAK patient, 14 CAD patients and no control subjects
had a recent MI (<_3 months of CCTA).
....................................................................................................................................................................................................................
Table 1 Baseline clinical factors
TAK with CAD TAK without CAD Atherosclerotic CAD Controls
Number of subjects 36 18 32 22
Age, years, median (IQR) 53 (43–59) 42 (33–55) 65 (59–73) 52 (42–62)
Female, n (%) 32 (89) 16 (89) 6 (19) 12 (55)
Median body mass index, kg/m2, median (IQR) 27 (23–30) 28 (23–33) 29 (26–31) 27 (23–32)
Cardiovascular risk factors, n (%)
Hypertension 20 (56) 6 (33) 19 (58) 8 (36)
Hypercholesterolaemia 25 (70.37) 1 (6) 24 (75) 6 (27)
Noninsulin dependent diabetes 5 (14) 2 (11) 5 (16) 1 (5)
Smoking habit (ex or current) 24 (67) 10 (56) 22 (69) 6 (27)
Other medical history, n (%)
Stable angina 4 (11) 0 12 (38) 0
Myocardial infarction 3 (8) 0 16 (50) 0
Percutaneous coronary intervention 3 (8) 0 16 (50) 0
Coronary artery bypass grafting surgery 5 (14) 0 0 0
Transient ischaemic attack or ischaemic
stroke
3 (8) 0 4 (13) 0
Peripheral vascular disease 0 1 (6) 2 (6) 0
Current medications, n (%)
Statin 19 (53) 5 (28) 28 (87.50) 0
Anti-hypertensive 9 (25) 7 (39) 27 (84.38) 0
Corticosteroid 25 (69) 15 (8) 0 0
Methotrexate 4 (11) 2 (11) 0 0
Azathioprine 3 (1) 0 0 0
Cyclophosphamide 1 (23) 0 0 0
Anti-TNFa 2 (6) 0 0 0
Tocilizumab 1 (0.3) 0 0 0
Median lipid profile, mmol/L (IQR)
Total cholesterol 5.20 (4.00–6.00) 5.60 (5.10–5.90) 3.90 (3.25–5.03) 4.70 (4.40–6.15)
Triglycerides 1.56 (1.10–2.33) 1.11 (1.07–1.73) 1.59 (0.98–1.83) 1.00 (0.86–1.72)
HDL cholesterol 1.39 (1.23–1.62) 1.60 (1.25–1.81) 0.98 (0.89–1.18) 1.56 (1.41–1.83)
LDL cholesterol 2.77 (2.12–3.72) 3.35 (2.69–3.50) 2.18 (1.61–3.14) 2.75 (2.23–3.70)
Median high-sensitivity C-reactive protein, mg/L
(IQR)
5.05 (2.85–12.18) 3.90 (2.10–20.20) 2.80 (1.50–5.49) —
Median 10-year cardiovascular risk score, %
(IQR)
13 (10–18) 2 (2–5) 22 (15–33) 2.5 (1–7)
Median kV (IQR) 120 (120–120) 120 (120–120) 120 (100–140) 120 (80–120)



































..PCATand PAAT density by group
A total of 1016 coronary segments [median 10 (IQR 9–10) segments
per patient] and 108 aortic segments were analysed. PCAT density
varied across study groups, with higher mPCATtotal, mPCATprox and
PCATpRCA (P < 0.0001 for all) in TAK than atherosclerotic CAD or
controls (Figure 2; Supplementary material online, Table S1).
mPCATtotal was highly correlated with mPCATprox [r = 0.91 (95%
confidence interval, CI 0.86–0.94), P < 0.0001] and mPCATpRCA
[r = 0.81 (95% CI 0.73–0.87), P < 0.0001]. PAAT was also highly cor-
related with PCAT [mPCATtotal: r = 0.66 (95% CI 0.54–0.76);
mPCATprox: P = 0.60 (95% CI 0.46–0.71); pPCATpRCA: r = 0.52 (95%
CI 0.36–0.65); P < 0.0001 for all] and was increased more in TAK
than CAD and controls (P = 0.0002).
There was no difference in PCAT density between TAK and TAK
þ CAD groups. For patients with stable atherosclerotic CAD who
did not have a recent MI, PCAT density was higher than controls
when assessed using mPCATprox [-74.47 HU (-79.80, -69.70) vs.
-80.65 (-86.02, -74.35), P = 0.01]; however, there was only a trend to-
wards significance with PCATpRCA (P = 0.08) and no difference with
mPCATtotal.
When comparing individual coronary segments, increased PCAT
density was confirmed in TAK þ CAD compared to stable athero-
sclerotic CAD (effect size 7.01± SEM 1.78 HU, P = 0.0002) and TAK
without CAD compared to controls (effect size 8.20 ± SEM 2.04 HU,
P = 0.0001).
Distrubution of PCAT density within the
coronary tree
When examining the distribution of PCAT density around individual
coronary segments, higher values were observed around proximal,
compared to mid or distal vessels in all groups (effect size TAK þ
CAD: 9.18± SEM 0.90 HU, P < 0.0001; TAK: 12.46 ± SEM 1.35 HU,
P < 0.0001; CAD: 10.02 ± SEM 1.21 HU, P < 0.0001; control:
4.72 ± SEM 1.11 HU, P < 0.0001). Although PCAT density appeared
slightly less varied along the coronary tree in TAK than CAD when
visualized graphically (Supplementary material online, Figure S2),
there was no statistical difference in variance.
Diagnostic accuracy of PCATand PAAT
for TAK
All mPCAT metrics (mPCATtotal, mPCATprox, mPCATpRCA) and
PAAT had good accuracy for differentiating patients with TAK þ
CAD from stable atherosclerotic CAD, and TAK without CAD from
controls on ROC analysis (Figure 3; Supplementary material online,
Table S2). mPCATtotal density above -77 HU demonstrated 72%
Figure 1 PCAT density in a patient with TAK and bilateral coronary aneurysms. Coronary computed tomography angiography showing calcified
aneurysms of the (A) right coronary artery and the (B) left main coronary artery in a 28-year-old woman with TAK, with significant coronary stenoses
immediately distal to the aneurysms. PCAT density displayed using colour heatmap is increased around these vessels, as shown in (C and D) cross-sec-
tion and curved multi-planar views. PCAT, pericoronary adipose tissue; TAK, Takayasu arteritis































sensitivity and 72% specificity for differentiating patients with TAK þ
CAD compared to stable atherosclerotic CAD [area under the curve
(AUC) = 0.76 (95% CI 0.60–0.88)]. mPCATtotal density above -76
HU demonstrated 78% sensitivity and 86% specificity for TAK with-
out CAD, compared to controls [AUC = 0.86 (95% CI 0.72–0.97)].
For all subjects, mPCATtotal density above -76 HU demonstrated
70% sensitivity and 67% specificity for TAK vs. non-TAK [AUC = 0.73
(95% CI 0.63–0.82)].
Clinical markers of disease activity
mPCATtotal demonstrated the strongest correlations with clinical
markers of disease severity, compared to mPCATprox, mPCATpRCA
and PAAT (Figure 4; Supplementary material online, Table S3) and
was correlated with ITAS-CRP score (r = 0.43, P = 0.001) in TAK
patients, and C-reactive protein concentration (r = 0.41, P < 0.0001)
and erythrocyte sedimentation rate (r = 0.41, P = 0.002) in all patients.
PAAT had the strongest associations with total white cell count
(r = 0.25, P = 0.01) and neutrophil count (r = 0.29, P = 0.003). There
were no correlations identified between PCAT or PAAT density and
lipid profile, body mass index, 10-year %cardiovascular risk, or
%plaque burden.
Disease activity status
PCAT density was higher in active than inactive TAK (mPCATtotal:
P = 0.0002; mPCATprox: P = 0.004; mPCATpRCA: P = 0.0002; PAAT: P
= ns; Figure 3; Supplementary material online, Table S4). PCAT density
was also higher in CAD patients with recent MI than stable disease
(mPCATtotal: P = 0.008; mPCATprox: P = 0.002; mPCATpRCA: P = ns;
PAAT: P = ns). All mPCAT metrics had good accuracy for differenti-
ating active from inactive TAK and recent MI from stable CAD
(Supplementary material online, Table S2). mPCATtotal density above
-74 HU had 100% sensitivity and 95% specificity for active TAK com-
pared to controls [AUC = 0.99 (95% CI 0.97–1)].
The univariable linear mixed-effects model confirmed higher
PCAT density in coronary segments from active TAK patients than
inactive (effect size 5.78 ± SEM 1.92 HU, P = 0.004), and from CAD
patients with recent MI than stable disease (effect size 6.83 ± SEM
2.02 HU, P = 0.002). The association between PCAT density and
Figure 2 Distribution of PCAT density by disease group. Violin plots showing the distribution [dashed lines: median (interquartile range)] of PCAT
density across the four study groups for all coronary segments (mPCATtotal), proximal segments (mPCATprox) proximal right coronary artery seg-
ments (PCATpRCA), and PAAT density. CAD, coronary artery disease; HU, Hounsfield Unit; PAAT, periaortic adipose tissue; PCAT, pericoronary adi-
pose tissue; TAK, Takayasu arteritis; ****P < 0.0001; ***P < 0.001.
























.TAK disease activity status remained in patients with aortic thickening
(effect size 6.37± SEM 2.32 HU, P = 0.01) and ostial involvement (ef-
fect size 8.20 ± SEM 2.54 HU, P = 0.004).
In the only TAK patient with recent MI, PCAT density surrounding
the culprit coronary segment on CCTA performed within one day of
symptoms (prior to stenting), was increased (Figure 5). However, in
the 13 CAD patients with recent MI [MI to CCTA interval: median
19 (IQR 15–29) days; 12 of 13 culprit vessels stented], PCAT density
was similar surrounding culprit and non-culprit segments.
PET imaging of arterial inflammation
Coronary 68Ga-DOTATATE PET scans were analysed in three TAK
patients and 29 CAD patients [CCTA to PET scan interval: median 8
(IQR 0–31) days]. PCAT density was moderately correlated with 68Ga-
DOTATATE TBRmax in coronary segments from CAD patients (Figure
6). In a pooled analysis of all 32 patients with 68Ga-DOTATATE imaging
performed using a linear mixed-effect model, there was a positive associ-
ation between PCAT density and coronary 68Ga-DOTATATE uptake,
which equated to an increase of 2.44± SEM 0.77 HU for each unit in-
crease in TBRmax (P= 0.002). A similar relationship between PCAT dens-
ity and 68Ga-DOTATATE uptake occurred in the CAD group alone
(effect size 2.35± SEM 0.77 HU, P= 0.003). The relationship between
68Ga-DOTATATE TBRmax and PCAT density was quantitatively similar
regardless of whether PET/CT or PET/MR was used to acquire the data.
Multivariable regression analyses
Of the potential confounding factors tested, age, anatomical location
of the coronary segment, current steroid use, recent MI, and kV dem-
onstrated P < 0.1 in the univariable linear mixed-effects analysis (full
list of variables in Supplementary material online, Table S5). These
Figure 3 Diagnostic accuracy of PCAT density in TAK. Receiver operating characteristic curves showing the diagnostic accuracy of PCAT density
for differentiating (A) patients with TAK and CAD from stable atherosclerotic CAD, and patients with TAK and no CAD from control subjects. (B)
Violin plots [dashed lines: median (interquartile range)] showing the distribution of PCAT density in patients with active versus inactive TAK, and re-
cent MI vs. stable atherosclerotic CAD. CAD, coronary artery disease; HU, Hounsfield Unit; MI, myocardial infarction; PCAT, pericoronary adipose
tissue; TAK, Takayasu arteritis; ***P < 0.001; **P < 0.01.


































.factors were included in the multivariable analyses to assess the ro-
bustness of the main study findings. Of note, gender, body mass index
and statin use were not found to be factors. After adjusting for con-
founders, higher PCAT density was confirmed in TAKþCAD vs. sta-
ble CAD (effect size 6.53 ± SEM 2.13 HU, P = 0.003) and TAK vs.
controls (effect size 7.88 ± SEM 2.39 HU, P = 0.001). The associations
between PCAT density and active TAK (effect size 4.16 ± SEM 1.90
HU, P = 0.03) and 68Ga-DOTATATE (effect size 2.56± SEM 0.71
HU, P = 0.0004) also remained.
Discussion
We found that PCAT and PAAT density on CCTA are higher in
patients with TAK than in atherosclerotic CAD or control sub-
jects, independent of potential patient-level confounding factors.
PCAT density was more closely linked with markers of clinical dis-
ease activity status in TAK than PAAT and was also associated
with coronary inflammation measured by 68Ga-DOTATATE PET.
This is the first study to investigate PCAT or PAAT density in TAK
patients, or to compare PCAT density with arterial 68Ga-
DOTATATE uptake in any disease group.
Use of PCAT density for risk-prediction
in CAD
Our findings are supportive of previous landmark studies that have
established PCAT density as a promising imaging biomarker for the
assessment of coronary arterial inflammation in atherosclerosis.
These studies have demonstrated that pericoronary FAI provides in-
cremental improvement for major adverse cardiac event prediction
above clinical risk factors and conventional CCTA measures,7 as well
as high-risk plaque CT feaures,8 and that specific radiomic features in-
dicative of adverse PCAT remodelling are also useful.9 Other studies
have shown an association with PCAT density and the progression of
CCTA-quantified plaque burden,10 and an ability to differentiate cul-
prit from non-culprit lesions.11
Indeed, PCAT density could be an important adjunct test for risk-
stratification in patients undergoing CCTA for investigation of CAD
in routine clinical care. The prognostic benefit of measuring PCAT
density could be even greater in patients with systemic inflammatory
conditions that are known to associate with accelerated coronary
atherosclerosis, such as psoriasis, systemic lupus erythematosus, and
rheumatoid arthritis. One study found that pericoronary FAI was
increased in patients with moderate-to-severe treatment-naı̈ve psor-
iasis, and modifiable by biologic therapy.12
Figure 4 PCAT density vs. PAAT density and clinical markers of disease activity. Scatter plots showing Spearman’s correlations between median
PCAT density and PAAT density, and clinical markers of disease activity. HU, Hounsfield Unit; PAAT, periaortic adipose tissue; PCAT, pericoronary
adipose tissue; TAK, Takayasu arteritis.







































..Emerging role of CCTA in TAK
CCTA is increasingly used as a first-line investigation for coronary in-
volvement in TAK; however, published literature on this topic is lim-
ited. Prior studies have reported CAD in 44% to 53% of TAK
patients undergoing CCTA, including atherosclerotic-type lesions,
ostial stenoses and aneurysms.13,14 Whether PCAT density could
help identify TAK patients with sub-clinical coronary involvement be-
fore the development of these complications is unknown. As a first
step towards understanding the relationship between coronary ar-
terial inflammation and PCAT density in TAK, we compared PCAT
density in patients with TAK (with and without CAD) to a typical
population of patients with atherosclerotic CAD, as well as matched
control subjects with no TAK or CAD. We also investigated PAAT
density in these patients, due to the nature of the disease as a large
vessel vasculitis.
Increased PCATand PAAT density in
TAK
We found that PCAT density was 7 HU greater in coronary seg-
ments from patients with TAK and CAD than stable atherosclerotic
CAD and 8 HU greater in TAK patients without CAD than control
subjects. PAAT density was similarly varied between groups and was
highly correlated with PCAT density (r = 0.67, P < 0.0001). As there is
no established method for assessing PCAT density in patients with
TAK, we explored different metrics (mPCATtotal, mPCATprox,
mPCATpRCA) and found the results to be largely consistent. By analy-
sing all epicardial coronary arteries with diameter >_2 mm, we were able
to better understand how arteritis affects the distribution of PCAT
density along the whole coronary tree and found these values in TAK
and CAD to be similarly distributed from proximal to distal vessels.
Diagnostic utility in TAK
An ability to differentiate vasculitic from atherosclerotic coronary
lesions in patients with TAK by non-invasive imaging is an unmet clin-
ical need. In this study, PCAT density had good diagnostic accuracy
for differentiating TAK patients with CAD from stable atherosclerot-
ic CAD (AUC 0.76) and TAK patients without CAD from control
subjects (AUC 0.86). Thus, in certain clinical scenarios increased
PCAT density could be a sensitive and specific marker of coronary ar-
teritis, as opposed to stable atherosclerosis, in TAK patients with cor-
onary lesions.
A novel marker of disease activity in
TAK?
PCAT density was increased more in TAK patients with active than
inactive disease, and was correlated with ITAS-CRP score, as well as
systemic markers of inflammation indicating that this novel imaging
biomarker could potentially provide clinically relevant informa-
tion about the inflammatory status of patients with TAK.
Moreover, PCAT density above -74 HU demonstrated an
Figure 5 PCAT density and 68Ga-DOTATATE PET/MRI in a patient with TAK and MI. Images from a 63-year-old woman with Takayasu arteritis
and coronary artery disease. At initial presentation with stable angina (A, C) coronary computed tomography angiography showed aortic thickening
(asterisks) and a proximal LAD artery stenosis (arrow), which was managed medically. (B) 3D reconstruction of the proximal LAD artery showing
the outer vessel wall (brown), lumen (blue), lipid (orange), and calcified (yellow) plaque components. (D) PCAT density displayed by colour heatmap
around the proximal LAD. Four years later, the same patient presented with a non-ST-segment elevation myocardial infarction [high-sensitivity
Troponin I 329 ng/L (normal range <41)]. (E) 68Ga-DOTATATE PET/MRI showed focal tracer uptake relating to the LAD lesion (arrow), subsequent-
ly identified by (F) angiography as the culprit artery (arrow). (H) Average PCAT density measured around the culprit LAD lesion prior to invasive angi-
ography and percutaneous stenting was increased. Atherosclerotic coronary plaque rupture with thrombosis (asterisk) was also confirmed by (G)
intravascular optical coherence tomography imaging before coronary stenting. LAD, left anterior descending; MRI, magnetic resonance imaging;
PCAT, pericoronary adipose tissue; PET, positron emission tomography.



































..impressive 100% sensitivity and 95% specificity for differentiating
patients with active TAK from control subjects (AUC 0.99). The
associations of PCAT density with clinical disease activity status in
TAK remained after adjustment for potential patient-level con-
founding factors and was also independent of the presence or ab-
sence of aortic thickening and ostial lesions. Thus, PCAT density
on CCTA could potentially offer a means of detecting persistent
arteritis despite treatment, which may not be readily apparent by
conventional imaging or blood tests.
While PAAT density was not higher in patients with active versus
inactive TAK, the majority of TAK patients were receiving long-term
immunosuppression for disease in remission at the time of CCTA,
and most patients with active disease were treated with corticoste-
roids. PAAT was also only measured in the proximal ascending aorta,
and not all active TAK patients would be expected to have vasculitis
involving the ascending aorta.
Consistency of CAD findings with other
studies
Although mPCATtotal demonstrated the best diagnostic accuracy for
TAK, previous studies performed in CAD patients have measured
PCAT density in only the proximal 40 mm of the major coronary
arteries, or the proximal right coronary artery. Overall, our findings
in CAD patients are consistent with previous studies when compar-
ing similar methodology.
For example, mPCATprox in CAD patients without recent MI was
-75 HU, which is similar to the proximal pericoronary FAI values
reported in the two cohorts of the CRISP-CT study (-75 HU and -77
HU),7 as well as another study that observed mean PCAT density
surrounding high-grade coronary stenoses of -76 HU.11 Although
there was no difference between PCAT density in patients with sta-
ble CAD who did not have a recent MI compared with control sub-
jects in our study using mPCATtotal, there was a difference using
mPCATprox.
Further corroboration of our findings in CAD patients is pro-
vided by a study that showed higher PCAT density in 60 patients
who underwent CCTA within 48 h of an acute MI, than stable
CAD patients and matched controls, as well as a lack of associ-
ation with plaque burden; both of these observations were repli-
cated in our study.15 Moreover, the repeatability of the same
validated method employed in our study was demonstrated in a
post hoc analysis of 50 consecutive patients who underwent
CCTA for investigation of suspected CAD in SCOT-HEART,
which showed intra- and interobserver interclass-coefficients of
0.999 and 0.998, with mean absolute differences for these meas-
urements of 0.05 and 0.13, respectively.4
Figure 6 PCAT density compared to coronary 68Ga-DOTATATE PET. (A) Scatter plots showing Spearman’s correlation for PCAT density and
68Ga-DOTATATE uptake in coronary segments from patients with TAK and CAD (n = 3) from the PITA study and atherosclerotic CAD (n = 28)
from the VISION and RIPPLE studies. (B) Representative coronary computed tomography angiography image from a patient with active TAK and ar-
terial thickening adjacent to the left main coronary ostium (asterisks) with no luminal impingement, demonstrating increased 68Ga-DOTATATE up-
take on PET/MRI (arrow), and corresponding increased PCAT density. HU, Hounsfield Unit; MRI, magnetic resonance imaging; PCAT, pericoronary
adipose tissue; PET, positron emission tomography; TAK, Takayasu arteritis; TBRmax, maximum tissue-to-blood ratio.

























..Associations with PET imaging
18F-FDG is often included in the diagnostic work-up of patients with
TAK, and has been extensively studied in the context of vasculitis and
atherosclerosis.16 However, arterial 18F-FDG uptake is also observed
in a high proportion of patients with clinically inactive TAK, where it
may represent vessel wall remodelling, atherosclerosis, or another
process besides inflammation.17 Moreover, coronary 18F-FDG imag-
ing is precluded in up to 50% of patients in research studies despite
dietary modification, because of avid myocardial muscle uptake.16
68Ga-DOTATATE is an alternative PET tracer that may provide a
more accurate readout of arterial inflammation than 18F-FDG, with
lower physiological myocardial signal.5 Initial data in large vessel vas-
culitis are encouraging.18 However, an ability to measure coronary
arterial, or indeed periaortic, inflammation from CCTA alone, with-
out the use of PET, would be a great advantage in this disease group.
Very few studies have compared PCAT density with PET imaging. In
the initial publication that validated FAI as a marker of coronary arterial
inflammation, FAI was correlated with 18F-FDG uptake in subcutane-
ous adipose tissue, but this finding was not apparent in epicardial adi-
pose tissue surrounding the right coronary artery.3 It is possible that
myocardial signal contamination was a confounding factor in that study.
In another report, pericoronary 18F-FDG uptake on PET imaging was
found to be related to degree of angiographic coronary artery stenosis
in the adjacent artery.19 PCAT density has also been shown to co-local-
ize with areas of focal microcalcification in high-risk atherosclerotic pla-
ques detected by 18F-sodium fluoride PET.20 In our study, we observed
a moderate association between PCAT density and coronary artery in-
flammation detected by 68Ga-DOTATATE PET.
Study limitations
As an initial observational study aimed to investigate the use of a
novel imaging approach in a rare disease group, we acknowledge sev-
eral factors that could limit the generalizability of our findings to
wider patient populations. These limitations include demographical
differences between TAK and atherosclerotic CAD patient groups,
and the possibility of additional confounding factors not accounted
for by the matched control group and statistical models. However,
despite these differences, the fact that younger, predominately female
TAK patients without traditional cardiovascular risk factors had
higher PCAT density than a typical older patient with established ath-
erosclerotic disease remains an important finding. In the PET imaging
sub-analysis, although only 3 of the 32 patients who underwent 68Ga-
DOTATATE imaging had TAK, this was a completely novel explora-
tory endpoint aimed to compare PCAT density with PET imaging
across a range of cardiovascular disease patients; and was not
intended to inform specifically about its association in TAK. The im-
pact of technical limitations of coronary PET imaging, including the
physical properties of the radioligand, uncorrected motion artefacts
and partial volume errors also cannot be discounted.
Conclusion
Here we show that PCAT and PAAT density on CCTA are higher in
TAK patients than atherosclerotic CAD or control subjects and are
associated with clinical, biochemical, and PET imaging markers of in-
flammation. As a readily accessible measurement on CCTA, with im-
pressive diagnostic accuracy for active disease, PCAT density could
be a useful clinical adjunct for patients with TAK as well as athero-
sclerosis. This approach could offer a means to detect early coronary
involvement in TAK, before structural arterial injury manifests; to dif-
ferentiate active coronary arteritis from stable atherosclerosis; or to
identify persistent arteritis despite conventional therapy. Future stud-
ies are needed to investigate PCAT and PAAT density as novel imag-
ing biomarkers for risk-stratification of patients with TAK and/or
CAD who may benefit from existing or newly emerging anti-
inflammatory therapies.
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